Metastatic (Pragmatica - S2302)

Study Information

Status: Active, Recruiting

Study Details

View study details on clinicaltrials.gov.

Locations

Not Specified

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Description

Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-2475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

This trial is available at multiple Sutter Locations. Please contact one of the following about Study S2302-Pragmatica:

San Francisco: ClinicalResearch@sutterhealth.org

Palo Alto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org

PAMF/Fremont: Tanya Pozniansky pozniat@sutterhealth.org

East Bay: Vivian Leong, RN Leongv@sutterhealth.org

Sacramento: SIMR@sutterhealth.org

Modesto: Stephanie Edmondson edmondsons@sutterhealth.org

Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals1@sutterhealth.org

San Mateo: Stephanie Casal CasalSL@sutterhealth.org and Bonnie Chan ChanBW@sutterhealth.org

Principal Investigator

Deepti Behl, MD

Related Studies

The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity

Using EHR from a large healthcare system in Northern CA, we will study the impact of smoking, comorbidities, race on COVID-19 infection and disease severity.

Investigator: Jiang Li, Ph.D., MPH